Trans-epidermal Water LossNCT05711303
Study to Investigate the Effect of Superba Boost on the Skin
A study testing Superba Boost in people with Trans-epidermal Water Loss, run by Atlantia Food Clinical Trials at 1 site in Ireland.
Trial summary
Study to determine the effect of 12 weeks daily consumption of Superba Boost as compared to placebo on reduction in Trans-Epidermal Water-Loss (TEWL). Read more about this study
- Who is it for?
- Ages 20 to 50 yearsHealthy volunteers can take part
- Conditions the study is for
- Trans-epidermal Water Loss
- What is being tested?
- Superba Boost
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 70 participants
- Where
- 1 siteIreland
- Study dates
- 13 Mar 2019to 20 Dec 2019
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 50 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- To be eligible for inclusion, the subject must fulfil all of the following criteria:
- Be able to give written informed consent;
- Be aged between 20 and 50 years, inclusive;
- Trans-epidermal water loss score >10 and ≤ 24.9 g/m²/h;
- Be in general good health with no existing co-morbidities
- Have a low habitual consumption of fatty fish and seafood, defined as a frequency of twice per month or less;
Show all 10Show fewer
- Be willing to avoid all fish and seafood meals in the 4-days before each scheduled clinic visit;
- Be willing to maintain dietary habits and physical activity levels throughout the trial period;
- Be able to communicate well with the Investigator, to understand and comply with the requirements of the study, and be judged suitable for the study in the opinion of the Investigator;
- Willing \& able to consume the investigational product daily for the duration of the study.
Who cannot join
- The presence of any of the following criteria will exclude the subject from participating in the study:
- Pregnant or breastfeeding women; women planning to become pregnant during the study;
- Women of child-bearing potential who do not use an acceptable method of contraception;
- Suffer from photosensitivity;
- History of skin cancer;
- Are currently taking photosensitizing medication, or have done so in the previous 4 weeks;
Show all 23Show fewer
- Sunbed tanning or sunbathing in preceding 3 months, or planned sunbed tanning or sunbathing during the study period
- Taking supplements known to have an effect on skin (e.g. fish oil, coenzyme Q-10, garlic, lycopene, beta-carotene, etc.), or have done so in the previous 4 weeks, except for medically-prescribed supplements or natural health products.
- Supplements known not to have an effect on the skin (e.g. probiotics) are allowed, once the subject has been on a stable dose for greater than 3 months and are willing to continue this supplement for the duration of the study;
- Systolic blood pressure ≥160 mmHg, diastolic blood pressure ≥100 mmHg. Subjects receiving blood pressure medications, must be on stable dose for greater than 3 months;
- Known allergy to seafood;
- Are hypersensitive to any of the components of the test product;
- Disturbed absorption due to changes in the gastrointestinal tract (e.g., resections, diverticula, malabsorption, blind-loop syndrome);
- Known alcohol abuse (> 21 units of alcohol per week) or drug abuse within the previous year of screening;
- Clinically significant illness within 14 days prior to dosing;
- Current or recent (within 3 months of screening visit) changes in diet, which in the opinion of the Investigator, deviates from a normal diet (e.g. vegetarians may be acceptable, vegans are not acceptable);
- Planned major changes in life style (i.e. diet, dieting, exercise level, travelling) during the duration of the study;
- Has any health conditions that would prevent from fulfilling the study requirements, put the subject at risk or would confound the interpretation of the study results as judged by the investigator on the basis of medical history and routine laboratory test results;
- Are severely immunocompromised (HIV positive, transplant patient, on antirejection medications, on a steroid for >30 days, or chemotherapy or radiotherapy within the last year);
- Experiences alarm features such as weight loss, rectal bleeding, recent change in bowel habit (<3 months) or abdominal pain;
- Have a malignant disease or any concomitant end-stage organ disease;
- Individuals who, in the opinion of the investigator, are considered to be poor attendees or unlikely for any reason to be able to comply with the trial;
- Subjects receiving treatment involving experimental drugs. If the subject has been in a recent experimental trial, these must have been completed not less than 60 days prior to this study.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: A Randomised, Double-blinded, Parallel, Placebo-controlled Study to Investigate the Effect of Superba Boost (Krill Oil Concentrate) on Various Skin Parameters in Healthy Adult Subjects
Study to determine the effect of 12 weeks daily consumption of Superba Boost as compared to placebo on reduction in Trans-Epidermal Water-Loss (TEWL).
Read the detailed description
This study is a randomized, double-blind, placebo-controlled, parallel group trial in 70 healthy adult male and female subjects between 20 and 50 years. The primary objective is to assess whether Superba Boost krill oil administered at a dose of 1 g per day for 12 weeks (84 days) has a positive effect on the TEWL, skin hydration and elasticity. At screening, the subjects must have TEWL values of >10 g/m2/h and <24.9 g/m2/h when measured by a TWEAmeter, i.e. within the range defined as normal and healthy skin. The change in omega-3 index, defined as EPA and DHA as percentage of total fatty acids in red blood cells, will be measured and correlated to the changes in the skin parameters. The study consists of 4 visits: the screening visit (V1), baseline visit / week 0 / Start of treatment (V2), Interim / Week 6 (V3) and week 12 / end of treatment (V4) . In this study, subjects must have a low habitual consumption of fatty fish and seafood, defined as a frequency of twice per month or less will be recruited.
Each subject must fulfill all inclusion criteria and will not be allowed to meet any of the exclusion criteria.
- Conditions
- Trans-epidermal Water Loss
- Being tested
- Superba Boost
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Superba BoostDietary supplement
Also called Placebo
To assess changes in Trans-epidermal water loss (TEWL), measured at baseline and after 12 weeks of intervention using a TEWAMetre.
| Study group | Role | What they receive |
|---|---|---|
| Superba Boost | Active comparator | One 1000 mg capsule per day Superba Boost for 12 weeks Receives: Dietary Supplement: Superba Boost |
| Placebo | Placebo comparator | One 1000 mg capsule per day placebo for 12 weeks Receives: Dietary Supplement: Superba Boost |
What is being measured
The primary outcome is the main question the study is designed to answer.
To determine the effect of 12 weeks daily consumption of Superba Boost as compared to placebo on reduction in Trans-Epidermal Water-Loss (TEWL).
Reduction in Trans-epidermal water loss (TEWL), measured at baseline and after 12 weeks of intervention using a TEWAMetre.
Measured: 12 weeks.
Secondary outcomes (8)
To determine the effect of daily consumption of Superba Boost as compared to placebo on the reduction of Trans-epidermal water loss (TEWL),
Changes in Trans-epidermal water loss (TEWL) from baseline to 6 weeks after start of treatment, using a TEWAMetre
Measured: 6 weeks.
To assess the effect of daily consumption of Superba Boost as compared to placebo on changes in skin hydration
Changes in skin hydration from baseline (pre-study) to 6 weeks after start of treatment using a Corneometer
Measured: 6 week
To assess the effect of daily consumption of Superba Boost as compared to placebo on changes in skin hydration
Changes in skin hydration from 6 weeks of treatment until end-of-study using a Corneometer
Measured: 6 weeks
To assess the effect of daily consumption of Superba Boost as compared to placebo on changes in skin firmness (6 weeks)
Changes in skin firmness from baseline (pre-study) to 6 weeks after start of treatment using a Cutometer
Measured: 6 weeks
To assess the effect of daily consumption of Superba Boost as compared to placebo on changes in skin firmness
Changes in skin firmness from 6 weeks of treatment until end-of-study using a Cutometer
Measured: 6 weeks
To assess the effect of daily consumption of Superba Boost as compared to placebo on changes on subjective evaluation
Subjective evaluation by study subjects, using questionnaires at 6 weeks of treatment
Measured: 6 weeks
To assess the effect of daily consumption of Superba Boost as compared to placebo on changes on subjective evaluation
Subjective evaluation by study subjects, using visual analogue scale at 12 weeks of treatment lower scores indicating worse outcomes and higher scores indicating better outcomes.
Measured: 12 weeks
To assess the effect of daily consumption of Superba Boost as compared to placebo on changes on Omega-3 index
Omega-3 index (%), using a blood spot collected by fingerpick
Measured: 12 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Feb 2023
- Study start13 Mar 2019
- Primary completion12 Aug 2019
- Study completion20 Dec 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Trans-epidermal Water LossStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Subjects who successfully meet the eligibility criteria will be randomized on a 1:1 basis, to receive Superba Boost or Placebo.
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Outcomes assessor
- Enrolment
- 70 participants (actual)
Sponsor and investigators
- Lead sponsor
- Atlantia Food Clinical Trials
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Sally O'Shea, MD, Principal investigator, Atlantia Food Clinical Trials
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05711303
- Sponsor's protocol ID
- AFCRO-097
- Status last verified
- Feb 2023
- First submitted
- 25 Jun 2019
- Last updated
- 8 Feb 2023
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 8 Feb 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomised, Double-blinded, Parallel, Placebo-controlled Study to Investigate the Effect of Superba Boost (Krill Oil Concentrate) on Various Skin Parameters in Healthy Adult Subjects
- ClinicalTrials.gov ID
- NCT05711303
- Acronym / sponsor ID
- AFCRO-097
- Conditions
- Trans-epidermal Water Loss
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 70 participants (actual)
- Lead sponsor
- Atlantia Food Clinical TrialsIndustry (pharma, biotech, devices)
- Study start
- 13 Mar 2019 (actual)
- Primary completion
- 12 Aug 2019 (actual)
- Study completion
- 20 Dec 2019 (actual)
- First posted
- 3 Feb 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Study to determine the effect of 12 weeks daily consumption of Superba Boost as compared to placebo on reduction in Trans-Epidermal Water-Loss (TEWL).
Detailed description
This study is a randomized, double-blind, placebo-controlled, parallel group trial in 70 healthy adult male and female subjects between 20 and 50 years. The primary objective is to assess whether Superba Boost krill oil administered at a dose of 1 g per day for 12 weeks (84 days) has a positive effect on the TEWL, skin hydration and elasticity. At screening, the subjects must have TEWL values of >10 g/m2/h and <24.9 g/m2/h when measured by a TWEAmeter, i.e. within the range defined as normal and healthy skin. The change in omega-3 index, defined as EPA and DHA as percentage of total fatty acids in red blood cells, will be measured and correlated to the changes in the skin parameters. The study consists of 4 visits: the screening visit (V1), baseline visit / week 0 / Start of treatment (V2), Interim / Week 6 (V3) and week 12 / end of treatment (V4) . In this study, subjects must have a low habitual consumption of fatty fish and seafood, defined as a frequency of twice per month or less will be recruited.
Each subject must fulfill all inclusion criteria and will not be allowed to meet any of the exclusion criteria.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, care provider, outcomes assessor)
- Number of arms
- 2
- Model description
- Subjects who successfully meet the eligibility criteria will be randomized on a 1:1 basis, to receive Superba Boost or Placebo.
| Arm | Type | Receives |
|---|---|---|
| Superba Boost | Active comparator | Dietary Supplement: Superba BoostOne 1000 mg capsule per day Superba Boost for 12 weeks |
| Placebo | Placebo comparator | Dietary Supplement: Superba BoostOne 1000 mg capsule per day placebo for 12 weeks |
Who may qualify
- Ages
- 20 to 50 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (10 listed)
- Be able to give written informed consent;
- Be aged between 20 and 50 years, inclusive;
- Trans-epidermal water loss score >10 and ≤ 24.9 g/m²/h;
- Be in general good health with no existing co-morbidities
- Have a low habitual consumption of fatty fish and seafood, defined as a frequency of twice per month or less;
Key exclusion criteria (23 listed)
- The presence of any of the following criteria will exclude the subject from participating in the study:
- Pregnant or breastfeeding women; women planning to become pregnant during the study;
- Women of child-bearing potential who do not use an acceptable method of contraception;
- Suffer from photosensitivity;
- History of skin cancer;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Superba BoostAlso: PlaceboTo assess changes in Trans-epidermal water loss (TEWL), measured at baseline and after 12 weeks of intervention using a TEWAMetre. | Dietary supplement | Placebo, Superba Boost |
Primary outcome
To determine the effect of 12 weeks daily consumption of Superba Boost as compared to placebo on reduction in Trans-Epidermal Water-Loss (TEWL).
Time frame: 12 weeks.
Reduction in Trans-epidermal water loss (TEWL), measured at baseline and after 12 weeks of intervention using a TEWAMetre.
8 secondary outcomes
To determine the effect of daily consumption of Superba Boost as compared to placebo on the reduction of Trans-epidermal water loss (TEWL),
Time frame: 6 weeks.
To assess the effect of daily consumption of Superba Boost as compared to placebo on changes in skin hydration
Time frame: 6 week
To assess the effect of daily consumption of Superba Boost as compared to placebo on changes in skin hydration
Time frame: 6 weeks
To assess the effect of daily consumption of Superba Boost as compared to placebo on changes in skin firmness (6 weeks)
Time frame: 6 weeks
To assess the effect of daily consumption of Superba Boost as compared to placebo on changes in skin firmness
Time frame: 6 weeks
To assess the effect of daily consumption of Superba Boost as compared to placebo on changes on subjective evaluation
Time frame: 6 weeks
To assess the effect of daily consumption of Superba Boost as compared to placebo on changes on subjective evaluation
Time frame: 12 weeks
To assess the effect of daily consumption of Superba Boost as compared to placebo on changes on Omega-3 index
Time frame: 12 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Feb 2023.
- Individual participant dataSharing planned: No
Related trials for Trans-epidermal Water Loss
Recruiting
Clinical Study on the Medical Devices PROXERA PSOMED 20 and PROXERA PSOMED 40 for the Treatment of Plaque Psoriasis and Non-pustular Palmoplantar Psoriasis
Plaque Type Psorisis, Non-pustular Palmoplantar Psoriasis
Enrolling by invitation
A Study on the Efficacy of 2% Cholesterol Cream in Atopic Dermatitis
Atopic Dermatitis (AD), Cholesterol
RecruitingObservational study
Diabetic Foot Ulcer (DFU) Biofilm Infection and Recurrence
Chronic Wounds, Biofilm Infection
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Sally O'Shea, MD principal investigator
Atlantia Food Clinical Trials
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Superba Boost in people with Trans-epidermal Water Loss, run by Atlantia Food Clinical Trials at 1 site in Ireland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 10 inclusion and 23 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 8 Feb 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Ireland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
To determine the effect of 12 weeks daily consumption of Superba Boost as compared to placebo on reduction in Trans-Epidermal Water-Loss (TEWL). (time frame: 12 weeks.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Feb 2023.